Brain tumor trial aims to match patients with tailored drugs
NCT ID NCT06512311
First seen Apr 24, 2026 · Last updated Apr 30, 2026 · Updated 3 times
Summary
This study tests whether testing a patient's own tumor cells in a lab to find the most effective drugs can improve survival for people with a newly diagnosed, aggressive brain cancer called glioblastoma. About 240 adults aged 18-75 will take part. Half will receive standard treatment plus the personalized drug screening, while the other half receives standard treatment alone. The goal is to see if the personalized approach leads to longer survival and better quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH Vienna, Department for Internal Medicine I, Oncology
RECRUITINGVienna, State of Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.